Oncology experts shed light on progress of genetic testing and targeted therapies in lung cancer.
Erin Bastick, PharmD, RPh
There is no cure for HIV, but with proper medical treatment, the disease can be controlled.
Treatment failures can result in a spectrum of problems for patients with hemophilia. Here’s some guidance on choosing the right therapy.
More targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.
While targeted cancer therapies make up a big part of the pipeline, there are three areas that oncology experts want you to keep on your radar.
More support for clinical trials and a wider lens for rare diseases in children sets the category on fire.
As more specialty drugs are approved, cost control strategies are key.
The next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.
Cost burden prompts payers to consider appropriate utilization
Although drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.